Selection of the 5'-proximal translation initiation site is influenced by mRNA and eIF-2 concentrations.
A cDNA clone of the influenza virus NS (non-structural protein) gene in a vector carrying a bacteriophage T7 RNA polymerase promoter was manipulated so as to reiterate the initiation site to give two in-frame AUG codons 57 nucleotide residues apart. Each initiation site was in either a preferred context (...AUAAUGG...) or a less favourable context (...UUUAUGG...) and the four possible permutations were constructed. When capped mRNA transcripts of these clones were translated in the rabbit reticulocyte lysate system, products from initiation at both AUG codons were observed. At low RNA concentrations the frequency of initiation at the 5'-proximal AUG codon rather than the second was higher when the first AUG codon was in the preferred context, in qualitative agreement with the scanning ribosome model. However, a completely unexpected finding was that the ratio of initiation at the first AUG codon to initiation at the second decreased with increasing mRNA concentration, irrespective of the particular context involved. Several lines of evidence indicated that the increased frequency of initiation at the second AUG codon was not due solely to the lower density of ribosome loading per mRNA at high RNA concentrations, and may therefore be the result of high RNA concentrations out-titring the capacity of endogenous reticulocyte factors responsible for preferential initiation at the 5'-proximal AUG codon. The effect of supplementing the system with purified initiation factors was examined. Only eIF-2 was capable of decreasing the frequency of initiation at the second AUG codon and promoting use of the first AUG at high mRNA concentrations; eIF-3, 4A, 4B, 4C + 4D, 4F and 5 were inactive.
Dasso
M C
MC
Department of Biochemistry, University of Cambridge, England.
Milburn
S C
SC
Hershey
J W
JW
Jackson
R J
RJ
D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D003062:Codon / Q000187:drug effects*; D004247:DNA / Q000032:analysis; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015852:Eukaryotic Initiation Factor-2 / Q000494:pharmacology*; D005822:Genetic Vectors; D008969:Molecular Sequence Data; D009975:Orthomyxoviridae / Q000201:enzymology / Q000235:genetics*; D010448:Peptide Initiation Factors / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000187:drug effects; D014176:Protein Biosynthesis / Q000187:drug effects*; D012333:RNA, Messenger / Q000187:drug effects* / Q000494:pharmacology*; D011817:Rabbits; D012156:Reticulocytes / Q000378:metabolism; D012689:Sequence Homology, Nucleic Acid; D013604:T-Phages / Q000201:enzymology; D014764:Viral Proteins / Q000235:genetics
D003062:Codon; D015852:Eukaryotic Initiation Factor-2; D010448:Peptide Initiation Factors; D012333:RNA, Messenger; D014764:Viral Proteins; D004247:DNA; D012321:DNA-Directed RNA Polymerases